BACKGROUND: Currently there are over 1 billion smokers worldwide. While many cessation programs are available to assist smokers in quitting, research suggests that partner involvement may encourage long-term abstinence. The purpose of this review was to determine if an intervention to enhance partner support helps smoking cessation when added as an adjunct to a smoking cessation program. METHODS: The search was performed in Cochrane Tobacco Addiction Group specialized register and 10 other databases. The search terms used were smoking, smoking cessation, and support. The search was also limited to English language. Randomized controlled trials that included a partner support intervention and reported follow-up of 6 months or greater were selected. Abstinence was the primary outcome measure and was analyzed at 2 post-treatment intervals: 6-9 months and >12 months. A fixed-effects model was used to assess the summary effect of the studies. RESULTS: A total of 31 articles were identified for this review. Only 9 studies met the inclusion criteria. The definition of partner varied among the studies. There was limited biochemical validation of abstinence rates. The odds ratio for self report abstinence at 6-9 months was 1.08 (CI 95%, .81, -1.44) and at 12 months post-treatment was 1.0 (CI 95%, 0.75, 1.34). There were no numerical data values for biochemical validation (saliva cotinine/thiocyanate) and carbon monoxide levels at 6-9 months and/or >12 months follow-up. CONCLUSION: We concluded that interventions designed to enhance partner support for smokers in cessation programs did not increase quit rates. Limited data from several of the RCTs suggest that these interventions did not increase partner support either. No conclusions can be made about the impact of partner support on smoking cessation. More systematic intervention to affect partnership significantly should be delivered if partner support were part of an existing cessation program.
Carbon Monoxide ; Follow-Up Studies ; Odds Ratio ; Outcome Assessment (Health Care) ; Self Report ; Smoke* ; Smoking Cessation* ; Smoking* ; Tobacco

PURPOSE: Obesity is a significant risk factor for pelvic organ prolapse (POP), but the effects of obesity on outcomes of surgery for POP are poorly understood. The aim of this study was to assess the relationship between POP symptomatology, subjective outcomes of surgery and body mass index (BMI) in women undergoing vaginal hysterectomy for POP. METHODS: Pre- and postoperative data from a validated pelvic floor questionnaire (electronic Personal Assessment Questionnaire-Pelvic Floor) were collected prospectively from 60 women undergoing vaginal hysterectomy for POP. Of these, 20 were normal weight (BMI 18.5–24.9 kg/m²), 20 were overweight (BMI 25–29.9 kg/m²), and 20 were women with obesity (BMI 30–34.9 kg/m²). The relationship between BMI and symptom scores for prolapse, impact on vaginal symptoms on quality of life (VS-QoL) and ‘overall change in condition’ was assessed. Pre- and postoperative symptom scores were compared using repeated mixed analysis of variance test for BMI as a categorical variable (normal, overweight, and obese). Spearman rank order correlation test was carried out to evaluate BMI as a continuous variable. All women underwent vaginal hysterectomy using a standardized technique. RESULTS: Overall, 93% of women reported improvement in their condition. The main finding was that ‘overall change in condition’ was negatively correlated with increasing BMI (r(s)=-0.324, P=0.028). Irrespective of BMI, significant improvements were observed in symptoms of prolapse and VS-QoL at 3-month postoperation. CONCLUSIONS: With increasing BMI, women are likely to report lower levels of satisfaction following prolapse surgery, despite reporting equivalent improvements in symptoms. BMI is known to affect how individuals perceive their general health and well-being with obese individuals reporting poorer levels of subjective health status. Women with obesity may perceive change in their condition after prolapse surgery differently to women of normal weight. Reduction of weight prior to prolapse surgery could be considered in obese women to improve subjective outcomes of surgery.
Body Mass Index ; Diagnostic Self Evaluation ; Female ; Humans ; Hysterectomy ; Hysterectomy, Vaginal ; Obesity ; Overweight ; Patient Outcome Assessment ; Pelvic Floor ; Pelvic Organ Prolapse ; Prolapse ; Prospective Studies ; Quality of Life ; Risk Factors

Parenteral nutrition-associated liver disease (PNALD) is a liver dysfunction caused by various risk factors presented in patients receiving total parenteral nutrition (TPN). Omega-6 rich Intralipid® and omega-3 rich Omegaven® are two intravenous lipid emulsions used in TPN. TPN could affect the hepatic expression of genes in anti-oxidative stress, but it's unknown whether TPN affects genes in drug metabolism. In this study, either Intralipid®- or Omegaven®-based TPN was administered to mice and the expression of a cohort of genes involved in anti-oxidative stress or drug metabolism was analyzed, glutathione (GSH) levels were measured, and protein levels for two key drug metabolism genes were determined. Overall, the expression of most genes was downregulated by Intralipid®-based TPN ( and ). Omegaven® showed similar results as Intralipid® except for preserving the expression of and and increasing . Total GSH levels were decreased by Intralipid®, but increased by Omegaven®. CYP3A11 protein levels were increased by Omegaven®. In conclusion, TPN reduced the expression of many genes involved in anti-oxidative stress and drug metabolism in mice. However, Omegaven® preserved expression of , suggesting another beneficial effect of Omegaven® in protecting liver functions.